Celcuity (NASDAQ:CELC) Hits New 52-Week High – Here’s What Happened

Shares of Celcuity, Inc. (NASDAQ:CELC) hit a new 52-week high during trading on Thursday . The company traded as high as $121.12 and last traded at $118.6740, with a volume of 192497 shares traded. The stock had previously closed at $116.94.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Wells Fargo & Company assumed coverage on Celcuity in a research report on Friday, December 12th. They issued an “overweight” rating and a $126.00 price objective for the company. Wolfe Research reiterated an “outperform” rating and issued a $110.00 price objective on shares of Celcuity in a research report on Thursday, March 12th. Needham & Company LLC reiterated a “buy” rating and issued a $122.00 price objective on shares of Celcuity in a research report on Thursday, March 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, January 21st. Finally, Wall Street Zen upgraded Celcuity from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $109.88.

Celcuity Stock Performance

The company has a quick ratio of 10.55, a current ratio of 10.55 and a debt-to-equity ratio of 3.20. The stock has a market cap of $5.95 billion, a P/E ratio of -32.49 and a beta of 0.41. The stock has a fifty day simple moving average of $109.91 and a 200-day simple moving average of $94.23.

Celcuity (NASDAQ:CELC) last issued its earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.09. Equities analysts expect that Celcuity, Inc. will post -2.62 earnings per share for the current fiscal year.

Insider Transactions at Celcuity

In other Celcuity news, Director Richard E. Buller sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $110.27, for a total transaction of $330,810.00. Following the transaction, the director owned 6,760 shares in the company, valued at approximately $745,425.20. This trade represents a 30.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total value of $2,400,600.00. Following the transaction, the director owned 90,000 shares in the company, valued at approximately $10,802,700. This trade represents a 18.18% decrease in their position. The disclosure for this sale is available in the SEC filing. 15.77% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Celcuity

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CELC. Vanguard Group Inc. raised its position in shares of Celcuity by 23.5% during the third quarter. Vanguard Group Inc. now owns 2,059,047 shares of the company’s stock worth $101,717,000 after purchasing an additional 391,262 shares during the period. New York State Common Retirement Fund grew its holdings in shares of Celcuity by 68.0% during the third quarter. New York State Common Retirement Fund now owns 47,704 shares of the company’s stock worth $2,357,000 after buying an additional 19,313 shares in the last quarter. Atle Fund Management AB bought a new position in shares of Celcuity during the third quarter worth about $1,836,000. Candriam S.C.A. grew its holdings in shares of Celcuity by 48.3% during the third quarter. Candriam S.C.A. now owns 390,924 shares of the company’s stock worth $19,312,000 after buying an additional 127,348 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in shares of Celcuity by 2,142.0% during the third quarter. Nisa Investment Advisors LLC now owns 15,627 shares of the company’s stock worth $772,000 after buying an additional 14,930 shares in the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.